Galiximab
Monoclonal antibody
TypeWhole antibody
SourceChimeric (primate/human)
TargetCD80
Clinical data
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
KEGG
 ☒NcheckY (what is this?)  (verify)

Galiximab is a monoclonal antibody designed for the treatment of B-cell lymphoma.[1] As of September 2009, it is undergoing Phase III clinical trials.[2] The drug is a chimeric antibody from Macaca irus and Homo sapiens.[3]

References

  1. ^ Ebadi M, Sadeghi MA, Reddy NM, Rezaei N (2020). "Immunopathology and Immunotherapy of Non-Hodgkin Lymphoma". In Rezaei M (ed.). Cancer immunology: cancer immunotherapy for organ-specific tumors (Second ed.). Cham: Springer Nature. p. 178. ISBN 978-3-03-057949-4.
  2. ^ "Biogen Idec: Pipeline". Archived from the original on 2008-05-17. Retrieved 2009-09-24.
  3. ^ WHO Drug Information

External links


Immunosuppressive drugs / Immunosuppressants (L04)
Monoclonal antibodies for the immune system
Categories